- Home
- CDIO vs DWTX Comparison
CDIO vs DWTX Comparison
Compare CDIO & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- DWTX
- Stock Information
- Founded
- CDIO 2017
- DWTX 2012
- Country
- CDIO United States
- DWTX United States
- Employees
- CDIO N/A
- DWTX N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- DWTX
- Sector
- CDIO Health Care
- DWTX
- Exchange
- CDIO Nasdaq
- DWTX NYSE
- Market Cap
- CDIO 7.9M
- DWTX 9.2M
- IPO Year
- CDIO N/A
- DWTX N/A
- Fundamental
- Price
- CDIO $3.61
- DWTX $4.81
- Analyst Decision
- CDIO Buy
- DWTX Strong Buy
- Analyst Count
- CDIO 1
- DWTX 1
- Target Price
- CDIO $60.00
- DWTX $10.00
- AVG Volume (30 Days)
- CDIO 56.5K
- DWTX 41.4K
- Earning Date
- CDIO 08-11-2025
- DWTX 08-14-2025
- Dividend Yield
- CDIO N/A
- DWTX N/A
- EPS Growth
- CDIO N/A
- DWTX N/A
- EPS
- CDIO N/A
- DWTX N/A
- Revenue
- CDIO $19,902.00
- DWTX N/A
- Revenue This Year
- CDIO $1,434.82
- DWTX N/A
- Revenue Next Year
- CDIO $4,661.91
- DWTX N/A
- P/E Ratio
- CDIO N/A
- DWTX N/A
- Revenue Growth
- CDIO N/A
- DWTX N/A
- 52 Week Low
- CDIO $3.22
- DWTX $1.62
- 52 Week High
- CDIO $53.10
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- CDIO 32.36
- DWTX N/A
- Support Level
- CDIO $3.65
- DWTX N/A
- Resistance Level
- CDIO $4.18
- DWTX N/A
- Average True Range (ATR)
- CDIO 0.31
- DWTX 0.00
- MACD
- CDIO 0.12
- DWTX 0.00
- Stochastic Oscillator
- CDIO 4.49
- DWTX 0.00
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.